Dilara Atasoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dilara Atasoy has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Aysegul Cansu
Department of Radiology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
2 shared publications - Ayşe Füsun Bekirçavuşoğlu
Department of Radiology, Bursa City Hospital, 16250 Bursa, Türkiye
2 shared publications - Merve Erkan
University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Department of Radiology, Bursa, Turkey
2 shared publications - Ali Ahmetoğlu
Karadeniz Technical University, Faculty of Medicine, Department of Radiology, Trabzon, Turkey
1 shared publication - Christos M. Tolias
11Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London, UK
1 shared publication - Daniel Walsh
King’s College Hospital NHS Foundation Trust
1 shared publication
Latest Publications
- Open Access
- 6 January 2025
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 56 (1) , 1-11
Evaluatıon of contrast enhancement intensity, pattern, and kinetics of breast lesions on contrast-enhanced spectral mammography
Background: Contrast-enhanced spectral mammography (CESM) is a new and promising imaging modality that improves tumor visibility through tumor contrast enhancement caused by malignant neovascularization. Breast magnetic resonance imaging (MRI) is based on the principle that hypervascular lesions are stained more intensely with contrast material than the breast glandular tissue. Currently, contrast enhancement in contrast-enhanced mammography is used only as a tumor marker, and it is unclear whether it is possible to analyze the amount, pattern, and kinetics of contrast enhancement using this technique and the contribution of such analyses to the diagnostic process. Objective: To investigate the contribution of qualitative and semiquantitative data obtained from contrast-enhanced spectral mammography images to benign-malignant differentiation and their relationship with prognostic factors. Methods: This retrospective study included 64 patients who were treated between 2015 and 2019. A pathological breast craniocaudal (CC) radiograph was obtained 2 min after contrast. Following the standard procedure, pathological breast CC radiography was performed for approximately 6 min. The amount of contrast enhancement, contrast enhancement patterns, and kinetics of the breast lesions were analyzed qualitatively and/or semiquantitatively using contrast-enhanced mammography images. The contribution of the evaluated radiological parameters to the benign-malignant differentiation of tumors and their relationship with histopathological prognostic markers was also evaluated. Results: Nine benign and 55 malignant cases were identified in this study. The results showed that malignant tumors had a higher average contrast-to-noise ratio (CNR) than benign tumors, and a strong correlation was observed between semiquantitative and qualitative contrast amounts(R > 0.564, p ≤ 0.001). Benign tumors exhibited persistent enhancement, whereas malignant tumors showed plateau and washout enhancement patterns. Additionally, estrogen receptor (ER) positivity and tumor grade were linearly related to the degree of late-phase enhancement in malignant tumors. Patients with a high Ki-67 proliferation index were more likely to exhibit type-3 curves. Conclusions: Kinetic patterns and enhancement results of CESM can be utilized in the characterization of masses and may serve as a prognostic factor.
- 6 January 2025
- Published by Springer Nature in Egyptian Journal of Radiology and Nuclear Medicine
- Vol. 56 (1) , 1-11
Open AccessEvaluatıon of contrast enhancement intensity, pattern, and kinetics of breast lesions on contrast-enhanced spectral mammography
Background: Contrast-enhanced spectral mammography (CESM) is a new and promising imaging modality that improves tumor visibility through tumor contrast enhancement caused by malignant neovascularization. Breast magnetic resonance imaging (MRI) is based on the principle that hypervascular lesions are stained more intensely with contrast material than the breast glandular tissue. Currently, contrast enhancement in contrast-enhanced mammography is used only as a tumor marker, and it is unclear whether it is possible to analyze the amount, pattern, and kinetics of contrast enhancement using this technique and the contribution of such analyses to the diagnostic process. Objective: To investigate the contribution of qualitative and semiquantitative data obtained from contrast-enhanced spectral mammography images to benign-malignant differentiation and their relationship with prognostic factors. Methods: This retrospective study included 64 patients who were treated between 2015 and 2019. A pathological breast craniocaudal (CC) radiograph was obtained 2 min after contrast. Following the standard procedure, pathological breast CC radiography was performed for approximately 6 min. The amount of contrast enhancement, contrast enhancement patterns, and kinetics of the breast lesions were analyzed qualitatively and/or semiquantitatively using contrast-enhanced mammography images. The contribution of the evaluated radiological parameters to the benign-malignant differentiation of tumors and their relationship with histopathological prognostic markers was also evaluated. Results: Nine benign and 55 malignant cases were identified in this study. The results showed that malignant tumors had a higher average contrast-to-noise ratio (CNR) than benign tumors, and a strong correlation was observed between semiquantitative and qualitative contrast amounts(R > 0.564, p ≤ 0.001). Benign tumors exhibited persistent enhancement, whereas malignant tumors showed plateau and washout enhancement patterns. Additionally, estrogen receptor (ER) positivity and tumor grade were linearly related to the degree of late-phase enhancement in malignant tumors. Patients with a high Ki-67 proliferation index were more likely to exhibit type-3 curves. Conclusions: Kinetic patterns and enhancement results of CESM can be utilized in the characterization of masses and may serve as a prognostic factor.
- Open Access
- 3 January 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (1) , 73-80
Sarcopenia is associated with mortality in patients with COVID-19 independent of other demographic risk factors
Objectives: To investigate whether sarcopenia had an effect on in-hospital mortality independent from other demographic characteristics in patients with Coronavirus disease 2019 (COVID-19), and to determine a reliable cut-off value for sarcopenia if there is such a relationship. Methods: A total of 302 patients with COVID-19 were included in the study. Sarcopenia was assessed by indexed skeletal muscle mass at T12 vertebrae level (T12-SMI) on initial chest computed tomography (CT). A receiver operating characteristic (ROC) curve analysis was performed to detect a cut-off value of T12-SMI for mortality prediction. Then, sarcopenia was diagnosed by this value. Multivariable logistic regression analysis was used to detect independent variables for mortality. Results: Patients were separated into groups; 26 (8.6%) patients in the mortality group and 276 (91.4%) patients in the no-mortality group. In ROC analysis, cut-off values of 34.06 cm²/m² (sensitivity: 70%, specificity: 77%) in males and 29.36 cm²/m² (sensitivity: 67%, specificity: 69%) in females for T12-SMI were computed for mortality prediction. There were 110 (36.4%) patients with sarcopenia. Sarcopenia was more frequent in the mortality group than the no-mortality group (73.1% vs 33%, p < 0.001). In multivariate analysis age, previous cardiovascular and respiratory disease, and sarcopenia were independently associated with mortality in COVID-19 patients. Conclusions: A cut-off value of 34.06 cm²/m² in males and 29.36 cm²/m² in females for T12-SMI can be used to diagnose sarcopenia in patients with COVID-19. Sarcopenia is clearly associated with mortality in these patients.
- 3 January 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (1) , 73-80
Open AccessSarcopenia is associated with mortality in patients with COVID-19 independent of other demographic risk factors
Objectives: To investigate whether sarcopenia had an effect on in-hospital mortality independent from other demographic characteristics in patients with Coronavirus disease 2019 (COVID-19), and to determine a reliable cut-off value for sarcopenia if there is such a relationship. Methods: A total of 302 patients with COVID-19 were included in the study. Sarcopenia was assessed by indexed skeletal muscle mass at T12 vertebrae level (T12-SMI) on initial chest computed tomography (CT). A receiver operating characteristic (ROC) curve analysis was performed to detect a cut-off value of T12-SMI for mortality prediction. Then, sarcopenia was diagnosed by this value. Multivariable logistic regression analysis was used to detect independent variables for mortality. Results: Patients were separated into groups; 26 (8.6%) patients in the mortality group and 276 (91.4%) patients in the no-mortality group. In ROC analysis, cut-off values of 34.06 cm²/m² (sensitivity: 70%, specificity: 77%) in males and 29.36 cm²/m² (sensitivity: 67%, specificity: 69%) in females for T12-SMI were computed for mortality prediction. There were 110 (36.4%) patients with sarcopenia. Sarcopenia was more frequent in the mortality group than the no-mortality group (73.1% vs 33%, p < 0.001). In multivariate analysis age, previous cardiovascular and respiratory disease, and sarcopenia were independently associated with mortality in COVID-19 patients. Conclusions: A cut-off value of 34.06 cm²/m² in males and 29.36 cm²/m² in females for T12-SMI can be used to diagnose sarcopenia in patients with COVID-19. Sarcopenia is clearly associated with mortality in these patients.
- Open Access
- 1 January 2022
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 23 (1) , 32-37
Comparison of Different Slice Thicknesses on Chest Computed Tomography for Evaluation of COVID-19- Associated Pneumonia
Chest CT,COVID-19,slice thickness
- 1 January 2022
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 23 (1) , 32-37
Open AccessComparison of Different Slice Thicknesses on Chest Computed Tomography for Evaluation of COVID-19- Associated Pneumonia
Chest CT,COVID-19,slice thickness
- Open Access
- 3 November 2021
- Published by The European Research Journal in The European Research Journal
- Vol. 7 (6) , 601-609
Prevalence of aspirin and clopidogrel resistance in neurovascular stenting: a single-center experience
Objectives: The objective of this study was to determine the frequency of aspirin and clopidogrel resistance of patients undergoing neurovascular stenting procedure in the interventional radiology unit. Methods: The Multiplate® Analyzer (Roche Diagnostics, Germany) test data of 250 patients who underwent carotid or intracranial artery stenting due to atherosclerotic stenosis or treatment of intracranial aneurysms between 2013-2017 in the Interventional Radiology Unit of our hospital were evaluated retrospectively to detect the aspirin and clopidogrel resistance. Aspirin or clopidogrel resistance defined as the higher AUC value than 40U and 46U, respectively. The patients who did not have a result of the Multiplate® test; had anemia, known coagulation disorder or thrombocytopenia were excluded. Results: Among the 172 patients who met the inclusion criteria, 59 (34.3%) were those who had an intracranial stent during aneurysm treatment, and 113 (65.7%) had carotid stenting due to atherosclerotic stenosis. The prevalence of aspirin resistance was 9.4% (16/170) whereas that of clopidogrel resistance was 23.8% (41/172). Among the patients with atherosclerotic stenosis, aspirin resistance accounting for 3.6%, and clopidogrel resistance was 23.0%. Furthermore, the resistance in the patients with stent-assisted coiling for aneurysm treatment was 20.7% for aspirin and 25.4% for clopidogrel. Conclusions: In our study, the prevalence of aspirin resistance was found 9.4% and clopidogrel resistance 23.8% in patients who had neurovascular stenting. The effect of this condition on clinical outcomes in these patients should be investigated by randomized controlled trials.
- 3 November 2021
- Published by The European Research Journal in The European Research Journal
- Vol. 7 (6) , 601-609
Open AccessPrevalence of aspirin and clopidogrel resistance in neurovascular stenting: a single-center experience
Objectives: The objective of this study was to determine the frequency of aspirin and clopidogrel resistance of patients undergoing neurovascular stenting procedure in the interventional radiology unit. Methods: The Multiplate® Analyzer (Roche Diagnostics, Germany) test data of 250 patients who underwent carotid or intracranial artery stenting due to atherosclerotic stenosis or treatment of intracranial aneurysms between 2013-2017 in the Interventional Radiology Unit of our hospital were evaluated retrospectively to detect the aspirin and clopidogrel resistance. Aspirin or clopidogrel resistance defined as the higher AUC value than 40U and 46U, respectively. The patients who did not have a result of the Multiplate® test; had anemia, known coagulation disorder or thrombocytopenia were excluded. Results: Among the 172 patients who met the inclusion criteria, 59 (34.3%) were those who had an intracranial stent during aneurysm treatment, and 113 (65.7%) had carotid stenting due to atherosclerotic stenosis. The prevalence of aspirin resistance was 9.4% (16/170) whereas that of clopidogrel resistance was 23.8% (41/172). Among the patients with atherosclerotic stenosis, aspirin resistance accounting for 3.6%, and clopidogrel resistance was 23.0%. Furthermore, the resistance in the patients with stent-assisted coiling for aneurysm treatment was 20.7% for aspirin and 25.4% for clopidogrel. Conclusions: In our study, the prevalence of aspirin resistance was found 9.4% and clopidogrel resistance 23.8% in patients who had neurovascular stenting. The effect of this condition on clinical outcomes in these patients should be investigated by randomized controlled trials.
- Open Access
- 21 October 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (5) , 2396-2402
The utility of magnetic resonance angiography in children with nutcracker syndrome
Backgroun/Aim: The presented study aimed to evaluate the utility of Magnetic Resonance Angiography in the pediatric population with nutcracker syndrome. Patients with suggestive clinical symptoms and laboratory findings and got the diagnosis of nutcracker syndrome with Doppler ultrasonography between January 2011-2019 were included in the study. In addition, children who had renal MRA due to hypertension were evaluated as the control group. MRA images of all patients were examined retrospectively by 3 radiologists at different levels of experience, and the superior mesenteric artery angle, aorta-mesenteric distance, left renal vein diameter both in the regions of aorta-mesenteric and renal hilum were recorded. Forty-five patients diagnosed with nutcracker syndrome were included in the study. The mean age of patients was 12 (4-16) and 30 (67%) were female. As the control group, 25 patients with hypertension who had MRA were included and they had a mean age of 12 (1-18) and 19 (76%) were male. The mean superior mesenteric artery angle was 26.5 ° (16-73 ± 12) in the patient group and 57.8 ° (25-139, ± 33) in the control group (p <0.001); the mean aorta-mesenteric distance was 3.3 mm (1.7-6.5, ± 1.1) in the patient group and 8 mm (3.4-32, ± 5.9) in the control group (p <0.001). MRA measurements of 3 radiologists were consistent with each other. MRA imaging can be applied as an alternative diagnostic method for Doppler ultrasonography and Multidetector CT examinations by radiologists with different experience levels in pediatric patients with nutcracker syndrome.
- 21 October 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (5) , 2396-2402
Open AccessThe utility of magnetic resonance angiography in children with nutcracker syndrome
Backgroun/Aim: The presented study aimed to evaluate the utility of Magnetic Resonance Angiography in the pediatric population with nutcracker syndrome. Patients with suggestive clinical symptoms and laboratory findings and got the diagnosis of nutcracker syndrome with Doppler ultrasonography between January 2011-2019 were included in the study. In addition, children who had renal MRA due to hypertension were evaluated as the control group. MRA images of all patients were examined retrospectively by 3 radiologists at different levels of experience, and the superior mesenteric artery angle, aorta-mesenteric distance, left renal vein diameter both in the regions of aorta-mesenteric and renal hilum were recorded. Forty-five patients diagnosed with nutcracker syndrome were included in the study. The mean age of patients was 12 (4-16) and 30 (67%) were female. As the control group, 25 patients with hypertension who had MRA were included and they had a mean age of 12 (1-18) and 19 (76%) were male. The mean superior mesenteric artery angle was 26.5 ° (16-73 ± 12) in the patient group and 57.8 ° (25-139, ± 33) in the control group (p <0.001); the mean aorta-mesenteric distance was 3.3 mm (1.7-6.5, ± 1.1) in the patient group and 8 mm (3.4-32, ± 5.9) in the control group (p <0.001). MRA measurements of 3 radiologists were consistent with each other. MRA imaging can be applied as an alternative diagnostic method for Doppler ultrasonography and Multidetector CT examinations by radiologists with different experience levels in pediatric patients with nutcracker syndrome.
- Open Access
- 1 January 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (1) , 110-116
Diagnostic efficacy of routine contrast-enhanced abdominal CT for the assessment of osteoporosis in the Turkish population
This study aimed to evaluate the diagnostic efficacy of vertebral Hounsfield unit (HU) values on routine contrast- enhanced abdominal computed tomography (CT) scans for the assessment of osteoporosis using dual-energy X-ray absorptiometry (DXA) T-scores as a reference standard. A total of 111 consecutive patients who underwent contrast-enhanced abdominal CT examination for any indication and DXA within a 6-month period were retrospectively analyzed. The CT attenuation values of trabecular bone in HUs were measured in axial and sagittal planes from lumbar vertebrae 1–4 (L1–L4). The correlation between the DXA T-scores and HU values measured on the CT scans was evaluated by Pearson’s correlation test. Areas under the curves (AUCs) were calculated by receiver operating characteristic analysis for diagnostic proficiency, and threshold values were determined. Paired t-test and Bland–Altman plot test were used to evaluate the correlation between axial and sagittal HU values. There was a strong correlation between the DXA T-scores and HU values of all the lumbar vertebrae (P < 0.001). The highest correlation was for the L3 vertebra; L3 was thus chosen for additional analyses. The mean axial and sagittal L3 attenuations were 133.7 HU and 131.9 HU, respectively. The axial measurements were not significantly different from the sagittal measurements, with a mean difference of 1.8 HU (P > 0.05). The L3 axial CT attenuation threshold for 90% sensitivity was 170 HU and that for 90% specificity was 102 HU for distinguishing osteoporosis from osteopenia and normal bone mineral density (BMD). To distinguish the low BMD group from the normal group, the L3 axial CT attenuation threshold for approximately 90% sensitivity was 102 HU and for 90% specificity was 165 HU. The HUs derived from routine contrast-enhanced abdominal CT scans can be used for the evaluation of osteoporosis, without additional radiation exposure and cost.
- 1 January 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (1) , 110-116
Open AccessDiagnostic efficacy of routine contrast-enhanced abdominal CT for the assessment of osteoporosis in the Turkish population
This study aimed to evaluate the diagnostic efficacy of vertebral Hounsfield unit (HU) values on routine contrast- enhanced abdominal computed tomography (CT) scans for the assessment of osteoporosis using dual-energy X-ray absorptiometry (DXA) T-scores as a reference standard. A total of 111 consecutive patients who underwent contrast-enhanced abdominal CT examination for any indication and DXA within a 6-month period were retrospectively analyzed. The CT attenuation values of trabecular bone in HUs were measured in axial and sagittal planes from lumbar vertebrae 1–4 (L1–L4). The correlation between the DXA T-scores and HU values measured on the CT scans was evaluated by Pearson’s correlation test. Areas under the curves (AUCs) were calculated by receiver operating characteristic analysis for diagnostic proficiency, and threshold values were determined. Paired t-test and Bland–Altman plot test were used to evaluate the correlation between axial and sagittal HU values. There was a strong correlation between the DXA T-scores and HU values of all the lumbar vertebrae (P < 0.001). The highest correlation was for the L3 vertebra; L3 was thus chosen for additional analyses. The mean axial and sagittal L3 attenuations were 133.7 HU and 131.9 HU, respectively. The axial measurements were not significantly different from the sagittal measurements, with a mean difference of 1.8 HU (P > 0.05). The L3 axial CT attenuation threshold for 90% sensitivity was 170 HU and that for 90% specificity was 102 HU for distinguishing osteoporosis from osteopenia and normal bone mineral density (BMD). To distinguish the low BMD group from the normal group, the L3 axial CT attenuation threshold for approximately 90% sensitivity was 102 HU and for 90% specificity was 165 HU. The HUs derived from routine contrast-enhanced abdominal CT scans can be used for the evaluation of osteoporosis, without additional radiation exposure and cost.
- Open Access
- 14 November 2019
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (12) , 2094-2101
Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU)
BACKGROUND AND PURPOSE: The recently introduced Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield) is the third generation of Pipeline flow-diverter devices. It has a new stent-surface modification, which reduces thrombogenicity. We aimed to evaluate clinical and radiographic (safety and efficacy) outcomes of the Pipeline Shield. MATERIALS AND METHODS: The 30-day and 1-year mortality and morbidity rates and the 6- and 18-month radiographic aneurysm occlusion outcomes for procedures performed between March 2016 and January 2018 were analyzed. 3D-TOF-MRA was used for follow-up. RESULTS: Forty-four attempted Pipeline Shield procedures were performed for 41 patients with 44 target aneurysms (total of 52 aneurysms treated). A total of 88.5% of devices were inserted in the anterior circulation, and 11.5%, in the posterior circulation; 49/52 (94.2%) aneurysms were saccular; and 1/52 (1.9%) was fusiform. One (1.9%) aneurysm was an iatrogenic pseudoaneurysm, and 1 (1.9%) was a dissecting aneurysm. Seventy-one percent (35/49) of the saccular aneurysms were wide-neck (neck, >4 mm), 34.6% (18/52) were large (≥10 mm), and 3.8% (2/52) were giant (≥25 mm). The mean aneurysm sac maximal diameter was 9.0 mm, and the mean neck width was 5.0 mm. The cumulative mortality and morbidity rates were 2.3% and 6.8% at 1 year, respectively. The adequate occlusion rate was 78.8% at 6 months and 90.3% at 18 months. CONCLUSIONS: In this pragmatic and non-industry-sponsored study, the occlusion rates and safety outcomes were similar to those seen in previously published studies with flow-diverter devices and earlier generation Pipeline Embolization Devices.
- 14 November 2019
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (12) , 2094-2101
Open AccessOutcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU)
BACKGROUND AND PURPOSE: The recently introduced Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield) is the third generation of Pipeline flow-diverter devices. It has a new stent-surface modification, which reduces thrombogenicity. We aimed to evaluate clinical and radiographic (safety and efficacy) outcomes of the Pipeline Shield. MATERIALS AND METHODS: The 30-day and 1-year mortality and morbidity rates and the 6- and 18-month radiographic aneurysm occlusion outcomes for procedures performed between March 2016 and January 2018 were analyzed. 3D-TOF-MRA was used for follow-up. RESULTS: Forty-four attempted Pipeline Shield procedures were performed for 41 patients with 44 target aneurysms (total of 52 aneurysms treated). A total of 88.5% of devices were inserted in the anterior circulation, and 11.5%, in the posterior circulation; 49/52 (94.2%) aneurysms were saccular; and 1/52 (1.9%) was fusiform. One (1.9%) aneurysm was an iatrogenic pseudoaneurysm, and 1 (1.9%) was a dissecting aneurysm. Seventy-one percent (35/49) of the saccular aneurysms were wide-neck (neck, >4 mm), 34.6% (18/52) were large (≥10 mm), and 3.8% (2/52) were giant (≥25 mm). The mean aneurysm sac maximal diameter was 9.0 mm, and the mean neck width was 5.0 mm. The cumulative mortality and morbidity rates were 2.3% and 6.8% at 1 year, respectively. The adequate occlusion rate was 78.8% at 6 months and 90.3% at 18 months. CONCLUSIONS: In this pragmatic and non-industry-sponsored study, the occlusion rates and safety outcomes were similar to those seen in previously published studies with flow-diverter devices and earlier generation Pipeline Embolization Devices.